LIVE POLIO IRUS VACCINES

140 Safety-Field Evidence of Safety
TABLE 2A. T MARKER AND INTRACEREBRAL NEUROVIRULENCE OF TYPE 1 STRAINS EXCRETED BY
VACCINATED INDIVIDUALS
MONKEY
NEUROVIRULENCE
DAY AFTER
DIFFERENCE
VACCINEE VACCINE TCD60 LOG 10 LOG TITER AT
NUMBER FEEDING INOCULATED 40 C. AND 37 C. T MARKER
3 8 - 7.2 5.0 T
14/1 23 - 8.1 5.3 T
14/2 33 - 8.0 6.0 T
22 15 - 7.7 5.3 T
23 6 - 8.2 5.5 T
29/1 9 - 7.6 4.5 T
29/2 20 - 7.0 5.8 T
29/3 22 - 7.1 4.5 T
52/1 4 - 7.7 4.0 T
52/2 19 - 8.0 5.8 T
63 15 - 7.0 6.0 T
73 14 - 8.0 4.0 T
125 16 - 6.2 2.5 I
191 31 - 5.8 4.2 T
200 12 - 6.0 4.8 T
202/1 12 - 5.7 4.0 T
202/2 18 - 6.4 4.3 T
202/3 25 + 6.8 5.0 T
TABLE 2B. T MARKER AND INTRACEREBRAL NEUROVIRULENCE OF TYPE 2 STRAINS EXCRETED BY
VACCINATED INDIVIDUALS
MONKEY
NEUROVIRULENCE
DAY AFTER
DIFFERENCE
VACCINEE VACCINE TCDso LOG 10 LOG TITER AT
NUMBER FEEDING INOCULATED 400C. AND 370C. T MARKER
23 17 - 8.4 5.2 T
30/1 15 - 7.8 4.0 T
30/2 23 - 8.4 4.7 T
43 5 - 7.0 4.2 T
44 7 - 6.4 3.0 I
73 13 - 6.5 4.0 T
106 6 - 6.3 4.0 T
185/1 7 - 5.7 5.0 T
185/2 21 - 5.2 4.2 T
187 15 - 5.4 4.2 T
188 22 - 4.8 3.5 I
190 7 - 5.0 3.0 I
196/1 5 - 4.0 4.0 T
196/2 14 - 5.7 4.0 T
196/3 19 - 5.3 4.0 T
202 12 - 5.0 2.0 I